中药贯叶金丝桃治疗抑郁症的进展
The Progress of Chinese Traditional Medicine Hypericum perforatum L. for the Treatment of Depression
摘要: 抑郁症患病率逐年上升，社会负担不断加重，开发抗抑郁症药物已是当务之急。贯叶金丝桃又名圣约翰草，用于抑郁症治疗已有上千年历史，是目前替代经典抗抑郁合成药物治疗轻度和中度抑郁症的唯一草药。本文通过分析贯叶金丝桃治疗抑郁症的临床疗效和作用机理，为其成为安全有效的候选药提供证据，也为我国传统抗抑郁中草药的研究和开发提供参考。 With the increased prevalence of depression and social burden every year, the development of antidepressant is becoming a hop priority. Hypericum perforatum L., also known as St. John’sWort inEurope, has been used for the treatment of depression for thousands of years. It is the only herbal alternative to classic synthetic antidepressants in the therapy of mild to moderate depression. By analyzing the clinical antidepressant efficacy and mechanism of Hypericum perforatum L., it aims at providing some evidence for Hypericum perforatum L. as a safe and effective drug candidate, and also provides a reference for the research and development of our traditional antidepressant herb.

文章引用：吕琼琼, 刘巨源, 杨俊, 潘艳娟, 路璐. 中药贯叶金丝桃治疗抑郁症的进展[J]. 国际神经精神科学杂志, 2012, 1(3): 22-26. http://dx.doi.org/10.12677/IJPN.2012.13006

参考文献

[1] 丁香园. 2010年抗抑郁药市场研究报告[URL], 2012. http://d.dxy.cn/preview/2359551
[2] 米内网. 首届抗抑郁药物论坛在沪举行[URL], 2012. http://www.menet.com.cn/Articles/IEconomy/201110/20111013092308238_56373.html
[3] 中科院西北植物研究所. 秦岭植物志(第一卷, 第三册)[M]. 北京: 科学出版社, 1981: 303.
[4] 孙秋红. 抗抑郁良药——路优泰[J]. 河南实用神经疾病杂志, 2002, 5(2): 67.
[5] 中国医药经济信息网. 190亿美元: 抗抑郁药的豪门盛宴[URL], 2012. http://www.meinet.com.cn:8080/LocaleCompanyDynamic/showLocalCompanyDynamicDetailsAction.action?imId=98564599C 5314F42A332BAB3B1AB36F6.
[6] Nutrition Business Journal Chapter: Nutrition Business International. San Diego, 1998.
[7] 国家知识产权局. 中国知识产权网[URL]. http://www.cninfo.com.
[8] 成都康弘药业集团. 舒肝解郁胶囊前生今世[J]. 中国医院院长, 2011, 8: 76.
[9] K. Linde, G. Ramirez, C. D. Mulrow, et al. St John’s wort for depression—An overview and meta-analysis of randomised clini- cal trials. BMJ, 1996, 313(7052): 253-258.
[10] V. Butterweck, A. Wall, U. Lieflander-Wulf, et al. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry, 1997, 30 (Suppl. 2): 117-124.
[11] E. Kleber, T. Obry, S. Hippeli, et al. Biochemical activities of extracts from Hypericum perforatum L. 1st communication: Inhibition of dopamine-beta-hydroxylase. Arzneimittelforschung, 1999, 49(2): 106-109.
[12] R. B. Raffa. Screen of receptor and uptake-site activity of hypericin component of St. John’s wort reveals sigma receptor binding. Life Science, 1998, 62(16): 265-270.
[13] 石永平, 汪海. 高度富集黄酮类成分的贯叶连翘提取物抗抑郁作用[J]. 中药新药与临床药理, 2006, 17(1): 4-7.
[14] V. Butterweck, G. Jurgenliemk, A. Nahrstedt, et al. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Medica, 2000, 66(1): 3-6.
[15] M. Noldner, K. Schotz. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swim- ming test. Planta Medica, 2002, 68(7): 577-580.
[16] 张庆建, 赵毅民, 杨明等. 黄酮类化合物对中枢神经系统的作用 [J]. 中国中药杂志, 2001, 26(8): 511-513.
[17] G. Calapai1, A. Crupi, F. Firenzuoli, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry, 2001, 34(2): 45- 49.
[18] 徐立, 魏翠娥, 赵明波等. 贯叶金丝桃总黄酮对小鼠抑郁症模型的实验研究[J]. 中国中药杂志, 2005, 30(15): 1184-1188.
[19] N. Roz, M. Rehavi. Hyperforin inhibits vesicular uptake of mono- amines by dissipating pH gradient across synaptic vesicle mem- brane. Life Science, 2003, 73(4): 461-470.
[20] K. Treiber, A. Singer, B. Henke, et al. Hyperforin activates non- selective cation channels (NSCCs). British Journal of Pharma- cology, 2005, 145(1): 75-83.
[21] Y. Wang, Y. Zhang, J. He, et al. Hyperforin promotes mitochondrial function and development of oligodendrocytes. Journal of Neurochemistry, 2011, 119(3): 555-568.
[22] B. Kraus, H. Wolff, E. F. Elstner, et al. Hyperforin is a modula- tor of inducible nitric oxide synthase and phagocytosis in micro- glia and macrophages. Naunyn-Schmiedeberg’s Archives of Phar- macology, 2010, 381(6): 541-553.
[23] F. Borrelli, A. A. Izzo. Herb-drug interactions with St John’s wort (Hypericum perforatum): An update on clinical observa- tions. AAPS Journal, 2009, 11(4): 710-727.
[24] R. Groning, J. Breitkreutz and R. S. Muller. Physico-chemical interactions between extracts of Hypericum perforatum L. and drugs. European Journal of Pharmaceutics and Biopharmaceu- tics, 2003, 56(2): 231-236.
[25] L. Henderson, Q. Y. Yue, C. Bergquist, et al. St John’s wort (Hypericum perforatum): Drug interactions and clinical outcomes. British Journal of Clinical Pharmacology, 2002, 54(4): 349-356.
[26] A. A. Izzo. Drug interactions with St. John’s Wort (Hypericum perforatum): A review of the clinical evidence. International Journal of Clinical Pharmacology and Therapeutics, 2004, 42(3): 139-148.
[27] R. Madabushi, B. Frank, B. Drewelow, et al. Hyperforin in St. John’s wort drug interactions. European Journal of Clinical Phar- macology, 2006, 62(3): 225-233.
[28] R. S. Muller, J. Breitkreutz and R. Groning. Interactions be- tween aqueous Hypericum perforatum extracts and drugs: In vi- tro studies. Phytotherapy Research, 2004, 18(12): 1019-1023.
[29] L. Verotta, G. Appendino, E. Belloro, et al. Synthesis and biological evaluation of hyperforin analogues. Part I. Modification of the Enolized Cyclohexanedione Moiety, 2002, 65(4): 433-438.